Phase 2 N=101 AVERT Shock: Arginine Vasopressin During the Early Resuscitation of Traumatic Shock
Traumatic Shock
Primary: Number of Blood Products Transfused — 1.7; 3.0 Litre
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=66 Treatment of Post-SCI Hypotension
Spinal Cord Injury · Autonomic Dysreflexia · Orthostatic Hypotension
Primary: Affected Therapy Sessions — 16.4; 10.9 percentage of sessions
Phase 2 N=191 Field Trial of Hypotensive Versus Standard Resuscitation for Hemorrhagic Shock After Trauma
Blunt Trauma · Penetrating Wound · Hemorrhagic Shock
Primary: Total Volume of All Crystalloid Given for Early Resuscitation (Feasibility) — 2.04; 1.04; 1 liters
N/A N=119 Optimal Fluid Resuscitation for Trauma Patients
Trauma
Primary: Mortality — 0 participants
Phase 3 N=1,563 Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis
Septic Shock
Primary: Death Before Discharge Home by Day 90 — 14; 14.9 percentage of participants — p=0.61
N/A N=356 Orthostatic Hypotension Treatment on Rehab Unit
Orthostatic Hypotension · Falls
Primary: Orthostatic Hypotension at Discharge — 39; 44 Participants — p=0.6
Phase 4 N=337 Preventing Cardiovascular collaPse With Administration of Fluid Resuscitation Before Endotracheal Intubation
Acute Respiratory Failure · Intubation Complication
Primary: Number of Participants With Cardiovascular Collapse — 33; 31 Participants
N/A N=5 Biological Response of Trauma Patients to Standard Trauma Resuscitation Therapy
Hemorrhagic Shock
Primary: Biological Response as Characterized by Selected Cytokines, Specifically Tumor Necrosis Factor Alpha (TNFα), Interleukin One (IL-1β), and Interleukin Six (IL-6).
Phase 1 N=20 Intravenous AII for the Treatment of Severe Hypotension in High Output Shock: A Pilot Study
Septic Shock
Primary: Standing Dose of Norepinephrine Which is Required to Maintain a Mean Arterial Pressure (MAP) of 65 mmHg - Hour 1 — 7.4; 27.6 mcg/min
Phase 4 N=1,554 The Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care Trial
Septic Shock
Primary: 90-day Mortality — 323; 329 Participants
Phase 3 N=136 Midodrine for the Treatment of Refractory Hypotension
Hypotension · Critical Illness
Primary: Time Until Discontinuation of IV Vasopressors — 23.5; 22.5 hours
Phase 2 N=50 Resuscitative Endocrinology: Single-dose Clinical Uses for Estrogen-Traumatic Hemorrhagic Shock (RESCUE - Shock)
Hemorrhagic Shock
Primary: Survival — 16; 21 participants — p=.252
Phase 4 N=57 Loop Diuretics Administration and Acute Heart Failure
Acute Heart Failure
Primary: Evaluation of Mean Urine Output Volume During the Infusion Period — 2505; 2140 mL — p=0.04
Phase 4 N=157 Saline vs. Lactated Ringers for Emergency Department IV Fluid Resuscitation
Fluid Loss · Symptom Complex, Triple · Emergencies
Primary: Quality of Recovery-40 Score at 24 Hours — 166.8; 164.4 units on a scale — p=0.608
N/A N=120 Initiation of Hydrocortisone for the Treatment of Septic Shock
Septic Shock
Primary: 28-day Mortality — 19; 23 Participants
Phase 2 N=84 HCT+F vs. HCT Alone in Critically Ill Medical Septic Shock Patients
Septic Shock
Primary: Time to Resolution of Shock — 89; 84 Hours
Phase 4 N=29 Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis
Ascites · Cirrhosis
Primary: Time to Recurrence of Ascites. — 10; 8 days — p=<0.05
Phase 3 N=59 Impact of Intraoperative Fluid Management on Electrolyte and Acid-base Variables
Anesthesia
Primary: Change in Base Deficit — -1.5; -1.2; -0.5 mEq/L
N/A N=82 Fluid Balance in the ICU - Interventions to Minimize Fluids in Patients With Septic Shock
Septic Shock · Fluid Therapy · Hypotension
Primary: Cumulative Fluid Administered — 4417; 4110 mL of study fluid
Phase 3 N=45 Furosemide and Albumin for Diuresis of Edema: A Pilot Randomized Controlled Trial
Edema · Hypoproteinemia
Primary: Ventilator-free Days — 4; 13 days
N/A N=429 Predict Fluid Responsiveness in Spinal Anesthesia
Hypotension and Shock · Excessive Amount of Blood / Fluid Infusion
Primary: Percentage of Participants With Systemic Hypotensions — 68; 46; 65 Participants
Phase 3 N=196 Effects of Voluven on Hemodynamics and Tolerability of Enteral Nutrition in Patients With Severe Sepsis
Sepsis
Primary: Amount of Study Drug Required to Achieve Initial Hemodynamic Stabilization — 1379; 1709 Milliliter — p=0.0185
Phase 2 N=50 Corticosteroid Therapy in Refractory Shock Following Cardiac Arrest
Cardiac Arrest
Primary: Time to Shock Reversal — 55; 49 hours
N/A N=150 Fluid Responsiveness Evaluation in Sepsis-associated Hypotension
Sepsis · Hypotension
Primary: Fluid Balance — 0.65; 2.02 Liters — p=0.021
Phase 3 N=149 Use of 6% Hydroxyethylstarch (130/0.4) in Cardiac Surgical Patients
Postoperative Kidney Injury
Primary: Urine Neutrophil Gelatinase-associated Lipocalin (NGAL) [Time Frame: 24 Hours After Surgery] [Designated as Safety Issue: Yes] — 2.9; 4.0; 5.0; 4.7 ng/ml — p=0.15
N/A N=50 Effect of Remote Ischemic Conditioning on Trauma Patients With Hemorrhagic Shock
Hemorrhagic Shock
Primary: Neutrophil Oxidative Burst Activity — 302; 302; 298; 268 Median Fluorescence Intensity — p=0.56
Phase 3 N=300 Feasibility of 5% Albumin Compared With Balanced Crystalloid, as Intravenous Fluid Resuscitation in Adult Patients With Sepsis, Presenting as an Emergency to Hospital
Sepsis
Primary: Recruitment Rate — 150; 150 Participants
N/A N=974 Isotonic Solution Administration Logistical Testing
Acute Kidney Injury
Primary: Proportion of Isotonic Crystalloid Which is 0.9% Saline — 91.2; 21.0 Percentage of fluid that was saline — p=0.001
N/A N=10,100 Indication for Intraoperative Volume Therapy
Patients Undergoing Any Kind of Surgery
Primary: Number of Different Substitution Solutions Administered — 7827; 1055; 221 participants
Phase 3 N=57 Treating Brain Swelling in Pediatric Cerebral Malaria
Malaria, Cerebral
Primary: Number of Participants Who Died — 5; 5; 5 Participants